Griffiths Carrie L, Olin Jacqueline L
North Texas Veterans Health Care System, Dallas, TX 75216, USA.
J Pharm Pract. 2012 Jun;25(3):319-23. doi: 10.1177/0897190012442062. Epub 2012 May 2.
Triple negative breast cancer (TNBC), an aggressive variant of breast cancer, is characterized by lack of expression of the estrogen (ER) and progesterone receptors (PRs) and the human epidermal growth factor receptor (HER-2) that are commonly observed in other breast cancer subtypes. The TNBC subtype primarily occurs in younger women of African American or Hispanic descent and tumors tend to be high grade and initially responsive to chemotherapy. However, TNBC is characteristically aggressive with high recurrence, metastatic, and mortality rates. Treatment options are limited since the hormonal receptor and HER-2 antagonists typically used for other breast cancers are ineffective. As such, the mainstay of treatment of TNBC is traditional systemic cytotoxic chemotherapy. Potential future therapies for TNBC include targeted molecular strategies including poly (adenosine diphosphate ribose) polymerase (PARP) and epidermal growth factor receptor (EGFR) inhibitors and antiangiogenic agents. Further research aimed at identifying unique genetic characteristics of TNBC may allow development of other targeted molecular chemotherapy treatment options.
三阴性乳腺癌（TNBC）是一种侵袭性乳腺癌变体，其特征是缺乏雌激素（ER）和孕激素受体（PR）以及人表皮生长因子受体（HER-2）的表达，而这些受体在其他乳腺癌亚型中通常可以观察到。TNBC亚型主要发生在非裔美国或西班牙裔血统的年轻女性中，肿瘤往往分级较高，最初对化疗有反应。然而，TNBC具有侵袭性，复发率、转移率和死亡率都很高。由于通常用于其他乳腺癌的激素受体和HER-2拮抗剂无效，治疗选择有限。因此，TNBC治疗的主要手段是传统的全身细胞毒性化疗。TNBC未来潜在的治疗方法包括靶向分子策略，如聚（二磷酸腺苷核糖）聚合酶（PARP）和表皮生长因子受体（EGFR）抑制剂以及抗血管生成药物。旨在确定TNBC独特基因特征的进一步研究可能会带来其他靶向分子化疗治疗方案的发展。
